Educational Objectives

Needs Statement
- Urologists need a working understanding of novel and emergent TCCa tumor markers, of advances in intravesical therapy for superficial disease, and of novel radical surgical procedures.
- Urologists need to understand angiogenesis in the context of GU and prostate tumor biology, and from the standpoint of novel molecular targets for therapy.

Learning Objective 1:
At the conclusion of this continuing medical education activity, participants should be able to
- provide a state of the art update on molecular diagnosis, superficial disease therapy, and radical surgery in TCCa of the Bladder.
- provide an angiogenic biology and therapy target overview with an update on novel agents in use during clinical trials.

Strategies for Targeted Tumor Assessment and Elimination

1:00 p.m. – 1:15 p.m.
Welcome and Introduction
Robert Flanigan, MD
Presentation of SUO Young Investigator Awards
Robert Flanigan, MD
Presentation of CaP Cure Awards
Stuart S. Holden, MD
Program Overview: "Emergence of Molecular Biology in Urologic Tumor Diagnosis and Treatment"
Kenneth S. Koeneman, MD

2:45 p.m. – 3:15 p.m.
Willet F. Whitmore, Jr., Lecture
Introduction: Robert Flanigan, MD
The Evolving Role of the Urologist in Cancer Research
Jean B. deKernion, MD
Break

3:15 p.m. – 3:30 p.m.
Advances in Transitional Cell Carcinoma of the Bladder – Diagnosis and Therapy
Moderator: Seth Lerner, MD
Cost Effectiveness/Efficacy Algorithm Concerning Molecular Diagnosis of Bladder Carcinoma: With or Without Cytoscopy
Yair Lotan, MD
Advances in Detection of Bladder Carcinoma – Critical Comparison of Molecular Markers
Badrinath Konety, MD
Update on Interferon/BCG Intravesical Therapy: What’s Best on the Horizon?
Michael O’Donnell, MD
Mapping and Oncologic Outcomes of Extended Lymphadenectomy in Radical Cystectomy: How High is “High Enough”? (Case Studies)
John Stein, MD
Analysis/Debate/Panel Discussion
(Seth Lerner, MD; Arthur Sagalowsky, MD; William Bedford Waters, MD)
Adjourn

Disclosure Policy
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Urological Association Office of Education and Research, Inc., must insure balance, independence, objectivity and scientific rigor in all its sponsored activities.

All faculty participating in a CME accredited, sponsored program are expected to disclose to the audience any significant financial interest or other relationships with commercial supporters. The disclosures of each speaker are carefully reviewed by peers in preparation for the program and every effort made to mitigate and resolve those speaker conflicts with commercial supporters. The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine if the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion. When unlabeled or unapproved uses are discussed, these are also indicated.

Accreditation Statement
The American Urological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association takes responsibility for the content, quality and scientific integrity of this CME activity.

Credit Designation Statement
The American Urological Association Education and Research, Inc. designates this educational activity for a maximum of 3.25 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Unlabeled or Unapproved Use of Drugs or Devices
The audience is advised that one or more presentations in this continuing medical education activity may contain reference/s to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.